25-desacetylrifapentine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
25-desacetylrifapentine
Accession Number
DB15213
Description

25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 835.008
Monoisotopic: 834.441508832
Chemical Formula
C45H62N4O11
Synonyms
  • 25-DESACETYL RIFAPENTINE

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe metabolism of Acebutolol can be increased when combined with 25-desacetylrifapentine.
AcenocoumarolThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with Acenocoumarol.
AtenololThe metabolism of Atenolol can be increased when combined with 25-desacetylrifapentine.
BetaxololThe metabolism of Betaxolol can be increased when combined with 25-desacetylrifapentine.
BisoprololThe metabolism of Bisoprolol can be increased when combined with 25-desacetylrifapentine.
CarvedilolThe metabolism of Carvedilol can be increased when combined with 25-desacetylrifapentine.
CeliprololThe metabolism of Celiprolol can be increased when combined with 25-desacetylrifapentine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be increased when used in combination with 25-desacetylrifapentine.
DicoumarolThe risk or severity of bleeding can be increased when 25-desacetylrifapentine is combined with Dicoumarol.
EsmololThe metabolism of Esmolol can be increased when combined with 25-desacetylrifapentine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
29A0K44SJO
CAS number
79039-56-8
InChI Key
LPUNEQQTZOWCNO-WEOUFWGLSA-N
InChI
InChI=1S/C45H62N4O11/c1-23-12-11-13-24(2)44(57)47-35-30(22-46-49-19-17-48(18-20-49)29-14-9-10-15-29)40(54)32-33(41(35)55)39(53)28(6)42-34(32)43(56)45(7,60-42)59-21-16-31(58-8)25(3)37(51)27(5)38(52)26(4)36(23)50/h11-13,16,21-23,25-27,29,31,36-38,50-55H,9-10,14-15,17-20H2,1-8H3,(H,47,57)/b12-11-,21-16-,24-13-,46-22+/t23-,25+,26+,27-,31-,36-,37+,38+,45-/m0/s1
IUPAC Name
(7S,9E,11S,12S,13S,14R,15R,16R,17S,18S,19E,21E)-26-[(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl]-2,13,15,17,27,29-hexahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(29),2,4,9,19,21,25,27-octaene-6,23-dione
SMILES
CO[[email protected]]1C=CO[[email protected]@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(CC4)C4CCCC4)=C(NC(=O)\C(C)=C/C=C\[[email protected]](C)[[email protected]](O)[[email protected]@H](C)[[email protected]@H](O)[[email protected]@H](C)[[email protected]](O)[[email protected]@H]1C)C(O)=C2C(O)=C3C

References

General References
Not Available
ChemSpider
23976039

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentTuberculosis (TB)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0377 mg/mLALOGPS
logP4.38ALOGPS
logP3.26ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)6.99ChemAxon
pKa (Strongest Basic)7.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area214.08 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity232.84 m3·mol-1ChemAxon
Polarizability90.36 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:00 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates